Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21664740 | 1.00 | PLA2G2A (0.35) | PLA2G2AEPHX2HTTMEN1THRB | |
| SCHEMBL20324212 | 0.94 | ALDH1A1 (0.35) | PLA2G2AEPHX2HTTMEN1THRB | |
| SCHEMBL21664500 | 0.94 | ALDH1A1 (0.35) | PLA2G2AEPHX2HTTMEN1THRB | |
| SCHEMBL20372890 | 0.91 | EPHX2 (0.33) | PLA2G2AEPHX2HTTMEN1THRB | |
| SCHEMBL21664686 | 0.91 | EPHX2 (0.30) | EPHX2 | |
| SCHEMBL22374843 | 0.87 | ALDH1A1 (0.35) | PLA2G2AEPHX2HTTMEN1THRB | |
| SCHEMBL24763174 | 0.85 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL29331910 | 0.84 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL21472809 | 0.83 | USP2 (0.35) | PLA2G2AEPHX2HTTMEN1THRB | |
| SCHEMBL20231688 | 0.81 | USP2 (0.38) | PLA2G2AEPHX2HTTMEN1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | ARVINAS OPERATIONS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| WO-2020146470-A1 | Phosphatase Binding Compounds and Methods of Using Same | YALE UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | ARVINAS OPERATIONS, INC. | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139458-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | PLA2G2A 2658/4885EPHX2 924/4885HTT 254/4885 |
| US-11191741-B2 | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide | CRBN, MDM2, VHL | PLA2G2A 2752/4885EPHX2 1434/4885HTT 417/4885 |
| US-20180177750-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ENHANCER OF ZESTE HOMOLOG 2 POLYPEPTIDE | CRBN, MDM2, VHL | PLA2G2A 2752/4885EPHX2 1434/4885HTT 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.